Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids
Primary Purpose
Type II Diabetes Mellitus, Gestational Diabetes Mellitus
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Rotating fluids protocol
Insulin infusion protocol
Sponsored by
About this trial
This is an interventional prevention trial for Type II Diabetes Mellitus focused on measuring intrapartum, glycemic control, diabetes, insulin
Eligibility Criteria
Inclusion Criteria:
- Pregnant women with Type II diabetes mellitus or GDM controlled with insulin and/or hypoglycemic medication (GDMA2)
- Singleton pregnancies
- Gestational age between 37 0/7 weeks and 40 0/7 weeks
- Planned delivery at a Geisinger Medical Center (GMC) or Geisinger Wyoming Valley (GWV)
- English or Spanish speaking
- Anticipated delivery at ≥ 4 hours from randomization (e.g., cervical dilation at ≤ 7 cm at time of randomization)
Exclusion Criteria:
- Women with Type 1 diabetes mellitus or use of insulin pump
- Evidence of diabetic ketoacidosis at time of admission for delivery
- Multifetal gestation
- Gestational age < 37 0/7 weeks or > 40 0/7 weeks
- Non-English or Non-Spanish speaking
- Anticipated delivery < 4 hours from randomization (e.g., cervical dilation > 7 cm at time of randomization, first cesarean delivery of the day)
- Oral corticosteroid use within 48 hours of planned delivery
- Antenatal corticosteroid use within 7 days of admission for delivery
- Delivery planned outside of GMC or GWV
- Fetal demise
- Prenatal diagnosis of lethal fetal anomaly
- Active infection or immunocompromised state (e.g., HIV/AIDS, active malignancy, use of immunosuppressant medication) at time of admission for delivery
Sites / Locations
- GeisingerRecruiting
- Geisinger Wyoming ValleyRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Rotating fluids
Insulin infusion
Arm Description
Rotating fluids protocol will be initiated at the time of admission to Labor and Delivery.
Insulin infusion protocol will be initiated at the time of admission to Labor and Delivery.
Outcomes
Primary Outcome Measures
Neonatal blood glucose value
Neonatal blood glucose value from birth to 2 hours of life
Secondary Outcome Measures
Mean neonatal blood glucose value
Average of neonatal blood glucose values from birth to 24 hours of life
Incidence of maternal hypoglycemia
Blood glucose value < 50 mg/dL without symptoms OR Blood glucose value < 70 mg/dL with symptoms such as perspiration, palpitations, tremor, weakness, anxiety
Mean intrapartum maternal blood glucose value
Average of maternal blood glucose values during labor
Maternal blood glucose value before delivery
Blood glucose value
Incidence of composite neonatal outcome
Neonatal hypoglycemia, NICU admission, neonatal hyperbilirubinemia, and neonatal respiratory distress syndrome
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03912363
Brief Title
Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids
Official Title
Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids: Randomized Controlled Trial (RCT)
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2019 (Actual)
Primary Completion Date
November 30, 2023 (Anticipated)
Study Completion Date
November 30, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Geisinger Clinic
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will determine whether rotating intravenous (IV) fluid is better than receiving insulin to control a baby's blood sugar after delivery in laboring women with diabetes. A computer will choose the method of controlling the participant's blood sugar while they are in labor.
Detailed Description
Diabetes complicates 6-9% of all pregnancies. Of those pregnancies, 90% of pregnant diabetics have gestational diabetes mellitus (GDM), while the remainder of patients have pre-existing diabetes mellitus (DM). Maternal hyperglycemia has a negative impact on maternal and fetal/neonatal health. Adverse neonatal outcomes include birth injuries, respiratory distress, and metabolic derangements such as hypoglycemia. The incidence of neonatal hypoglycemia is higher in pregnancies complicated by pre-existing DM (24-48%) when compared to patients with GDM (16-19%).
Neonatal hypoglycemia causes immediate and long-term morbidity. Treatment of hypoglycemia may require admission to the Neonatal Intensive Care Unit (NICU). The severity and duration of neonatal hypoglycemia raises concern for permanent neurologic damage to the neonate. Even transient episodes of neonatal hypoglycemia have been associated with neurodevelopmental impairment. It is imperative that measures be taken in diabetic mothers (both pre-existing and gestational) to minimize the risk of neonatal hypoglycemia. While antepartum maternal glucose control remains an important factor in preventing neonatal complications, prevention of maternal hyperglycemia during the intrapartum period has been shown to reduce the risk of neonatal hypoglycemia.
Therapies utilized for maternal intrapartum glycemic control across academic centers in the United States include the use of insulin and rotation of intravenous (IV) fluids. Although used in clinical practice for intrapartum glycemic control, the impact of rotating IV fluids on neonatal blood glucose is unknown. The potential for using rotating IV fluids to control intrapartum blood glucose has several advantages over using insulin for optimization of blood glucose. There is minimal risk of maternal hypoglycemia using IV fluids when compared to insulin therapy. There is also less risk of medication error. IV fluids are easily administered as they do not require separate peripheral access and are easily accessible on a Labor and Delivery (L&D) unit.
The investigators propose a randomized controlled trial (RCT) to assess the effect of maternal intrapartum glycemic control with rotating IV fluids compared to insulin infusion on neonatal blood glucose levels within two hours of birth. The investigators hypothesize neonates born to mothers managed by rotating fluids will have higher neonatal blood glucose levels (closer to normal range) within two hours of birth compared to neonates born to mothers managed by insulin infusion.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type II Diabetes Mellitus, Gestational Diabetes Mellitus
Keywords
intrapartum, glycemic control, diabetes, insulin
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
74 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Rotating fluids
Arm Type
Active Comparator
Arm Description
Rotating fluids protocol will be initiated at the time of admission to Labor and Delivery.
Arm Title
Insulin infusion
Arm Type
Active Comparator
Arm Description
Insulin infusion protocol will be initiated at the time of admission to Labor and Delivery.
Intervention Type
Other
Intervention Name(s)
Rotating fluids protocol
Intervention Description
IV fluids at a rate of 100-150 ml/hr will be administered:
For blood glucose < 100 mg/dL or less: IV fluids with 5% dextrose
For blood glucose between 101-140 mg/dL: IV fluids without 5% dextrose
For blood glucose > 140 mg/dL on two consecutive occasions: insulin infusion protocol (Study arm 2)
Intervention Type
Other
Intervention Name(s)
Insulin infusion protocol
Intervention Description
Regular insulin at 1 unit/ml AND IV fluids at a rate of 100-150 ml/hr will be administered:
For blood glucose < 80 mg/dL: No insulin AND IV fluids with 5% dextrose
For blood glucose 80-100 mg/dL: Insulin at 0.5 U/hr AND IV fluids with 5% dextrose
For blood glucose 101-140 mg/dL: Insulin at 1.0 U/hr AND IV fluids with 5% dextrose
For blood glucose 141-180 mg/dL: Insulin at 1.5 U/hr AND IV fluids with 5% dextrose
For blood glucose 181-220 mg/dL: Insulin at 2.0 U/hr AND IV fluid without dextrose
For blood glucose > 220 mg/dL: Insulin at 2.5 U/hr AND IV fluids without dextrose
Primary Outcome Measure Information:
Title
Neonatal blood glucose value
Description
Neonatal blood glucose value from birth to 2 hours of life
Time Frame
Within 2 hours of life
Secondary Outcome Measure Information:
Title
Mean neonatal blood glucose value
Description
Average of neonatal blood glucose values from birth to 24 hours of life
Time Frame
First 24 hours of life
Title
Incidence of maternal hypoglycemia
Description
Blood glucose value < 50 mg/dL without symptoms OR Blood glucose value < 70 mg/dL with symptoms such as perspiration, palpitations, tremor, weakness, anxiety
Time Frame
During labor (average time 24 hours)
Title
Mean intrapartum maternal blood glucose value
Description
Average of maternal blood glucose values during labor
Time Frame
During labor (average time 24 hours)
Title
Maternal blood glucose value before delivery
Description
Blood glucose value
Time Frame
Within one hour of delivery
Title
Incidence of composite neonatal outcome
Description
Neonatal hypoglycemia, NICU admission, neonatal hyperbilirubinemia, and neonatal respiratory distress syndrome
Time Frame
First 24 hours of life until discharge (average time 21 days)
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
14 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Pregnant women with Type II diabetes mellitus or GDM controlled with insulin and/or hypoglycemic medication (GDMA2)
Singleton pregnancies
Gestational age between 37 0/7 weeks and 40 0/7 weeks
Planned delivery at a Geisinger Medical Center (GMC) or Geisinger Wyoming Valley (GWV)
English or Spanish speaking
Anticipated delivery at ≥ 4 hours from randomization (e.g., cervical dilation at ≤ 7 cm at time of randomization)
Exclusion Criteria:
Women with Type 1 diabetes mellitus or use of insulin pump
Evidence of diabetic ketoacidosis at time of admission for delivery
Multifetal gestation
Gestational age < 37 0/7 weeks or > 40 0/7 weeks
Non-English or Non-Spanish speaking
Anticipated delivery < 4 hours from randomization (e.g., cervical dilation > 7 cm at time of randomization, first cesarean delivery of the day)
Oral corticosteroid use within 48 hours of planned delivery
Antenatal corticosteroid use within 7 days of admission for delivery
Delivery planned outside of GMC or GWV
Fetal demise
Prenatal diagnosis of lethal fetal anomaly
Active infection or immunocompromised state (e.g., HIV/AIDS, active malignancy, use of immunosuppressant medication) at time of admission for delivery
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michael J Paglia, MD, PhD
Phone
570-714-1099
Email
mjpaglia@geisinger.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Kajal Angras, DO
Phone
570-271-8160
Email
kangras@geisinger.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael J Paglia, MD, PhD
Organizational Affiliation
Geisinger Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Geisinger
City
Danville
State/Province
Pennsylvania
ZIP/Postal Code
17822
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael J Paglia, MD, PhD
Phone
570-714-1099
Email
mjpaglia@geisinger.edu
First Name & Middle Initial & Last Name & Degree
Kajal Angras, DO
Phone
570-271-8160
Email
kangras@geisinger.edu
First Name & Middle Initial & Last Name & Degree
Michael J Paglia, MD, PhD
First Name & Middle Initial & Last Name & Degree
Kajal Angras, DO
Facility Name
Geisinger Wyoming Valley
City
Wilkes-Barre
State/Province
Pennsylvania
ZIP/Postal Code
18711
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael J Paglia, MD, PhD
Phone
570-714-1099
Email
mjpaglia@geisinger.edu
First Name & Middle Initial & Last Name & Degree
Kajal Angras, DO
Phone
570-271-8160
Email
kangras@geisinger.edu
First Name & Middle Initial & Last Name & Degree
Michael J Paglia, MD, PhD
First Name & Middle Initial & Last Name & Degree
Kajal Angras, DO
12. IPD Sharing Statement
Citations:
PubMed Identifier
24945238
Citation
DeSisto CL, Kim SY, Sharma AJ. Prevalence estimates of gestational diabetes mellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007-2010. Prev Chronic Dis. 2014 Jun 19;11:E104. doi: 10.5888/pcd11.130415.
Results Reference
background
PubMed Identifier
30461693
Citation
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. Obstet Gynecol. 2018 Dec;132(6):e228-e248. doi: 10.1097/AOG.0000000000002960.
Results Reference
background
PubMed Identifier
18463375
Citation
HAPO Study Cooperative Research Group; Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008 May 8;358(19):1991-2002. doi: 10.1056/NEJMoa0707943.
Results Reference
background
PubMed Identifier
16893507
Citation
Rosenberg VA, Eglinton GS, Rauch ER, Skupski DW. Intrapartum maternal glycemic control in women with insulin requiring diabetes: a randomized clinical trial of rotating fluids versus insulin drip. Am J Obstet Gynecol. 2006 Oct;195(4):1095-9. doi: 10.1016/j.ajog.2006.05.051. Epub 2006 Aug 8.
Results Reference
background
PubMed Identifier
6753588
Citation
Golde SH, Good-Anderson B, Montoro M, Artal R. Insulin requirements during labor: a reappraisal. Am J Obstet Gynecol. 1982 Nov 1;144(5):556-9. doi: 10.1016/0002-9378(82)90227-7.
Results Reference
background
Learn more about this trial
Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids
We'll reach out to this number within 24 hrs